Ultrasmall Targeted Nanoparticles with Engineered Antibody Fragments for Imaging of HER2-overexpressing Breast Cancer

09 September 2019 09:30 - 10:05

  • Construction and efficient assembly of silica-based ultrasmall nanoparticle with anti-Her2 targeting antibodies
  • Targeted nanoparticles effectively localize to Her2 expressing tumors in vivo
  • Nanoparticles show low liver accumulation and high tumor to background ratios in vivo
  • Targeted nanoparticles have the potential for use in staging, risk stratification, treatment planning and development of next generation therapeutics.

Marcello Marelli, Senior Scientist Antibody Discovery and Protein Engineering, AstraZeneca